Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lyudmila Bazhenova

Hematology & Oncology San Diego, CA Medical Doctor

NPI 1093791006 CMS profile 140693

200 W Arbor Dr, San Diego, CA 92103

Open in the dashboard

General payments

$327,935

279 records reported · program years 2019–2025

Research payments

$14,836

Paid to them · 14 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$6,157,481 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Lyudmila Bazhenova of San Diego, CA is reported in the CMS Open Payments database as having received $327,935 across 279 general payments and $14,836 in research payments paid to them. Separately, studies naming them as principal investigator received $6,157,481 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $63,335 51
2024 General $42,257 47
2023 General $43,999 38
2022 General $37,141 26
2022 Research $7,010 3
2021 General $52,032 30
2021 Research $2,335 3
2020 General $29,719 29
2020 Research $5,491 8
2019 General $59,453 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lyudmila Bazhenova
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Lyudmila Bazhenova were reported at $63,335. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Lyudmila Bazhenova Hematology & Oncology median Middle half National median
2019 $59,453 $529 $121–$2,516 $163
2020 $29,719 $339 $82–$2,213 $114
2021 $52,032 $263 $49–$1,965 $132
2022 $37,141 $416 $103–$2,395 $149
2023 $43,999 $542 $125–$2,646 $160
2024 $42,257 $692 $141–$3,008 $164
2025 $63,335 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $55,996 43 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $38,476 26 payments
  3. Genentech USA, Inc. $26,550 26 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $22,169 20 payments
  5. Pfizer Inc. $19,614 9 payments
  6. Janssen Scientific Affairs, LLC $19,000 11 payments
  7. AbbVie, Inc. $16,014 14 payments
  8. Merck Sharp & Dohme Corporation $14,679 15 payments
  9. Janssen Biotech, Inc. $14,299 22 payments
  10. Novartis Pharmaceuticals Corporation $11,219 10 payments
  11. Other $89,920 83 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $278,860 121 payments
  2. Travel and Lodging $23,099 61 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,394 15 payments
  4. Food and Beverage $6,586 78 payments
  5. Honoraria $1,960 1 payment
  6. Education $36 3 payments
Products named General payments · program years 2019–2025
  1. TAGRISSO $33,447 23 payments
  2. RYBREVANT $30,890 30 payments
  3. TECENTRIQ $23,372 25 payments
  4. ALUNBRIG Oncology $21,703 15 payments
  5. LORBRENA $15,903 8 payments
  6. Alecensa $15,093 13 payments
  7. LIBTAYO $12,680 9 payments
  8. BRAFTOVI $11,490 7 payments
  9. ALUNBRIG Oncology $10,945 5 payments
  10. TABRECTA $10,719 8 payments
  11. Other $58,550 64 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $12,751 6 payments
  2. F. Hoffmann-La Roche AG $2,085 8 payments

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

301

Median for Hematology-Oncology: 604

Drug cost

$3,278,195

Median for Hematology-Oncology: $1,306,514

Branded share of claims

77.4%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tagrisso Osimertinib Mesylate Brand 166 $2,701,346
Lorbrena Lorlatinib Brand 15 $282,369
Tabrecta Capmatinib Hydrochloride Brand 14 $280,093
Eliquis Apixaban Brand 20 $13,318
Prochlorperazine Maleate Generic 25 $351
Dexamethasone Generic 14 $299
Ondansetron Odt Ondansetron Brand 18 $232
Ondansetron Hcl Generic 18 $147
Prednisone Generic 11 $39

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$60,154

Medicare's payments for the services billed

Medicare patients

112

Average age 73

Services billed

901

73 women, 39 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 75%
High blood pressure 66%
Arthritis 45%
Osteoporosis 31%
Ischemic heart disease 29%
Depression 28%
COPD 24%
Diabetes 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BRAFTOVI
  • Array BioPharma Inc. $6,519
$6,519 — —
RYBREVANT
  • Janssen Biotech, Inc. $5,156
$5,156 — —
LORBRENA
  • PFIZER INC. $2,520
$2,520 15 —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $1,650
$1,650 — —
LIBTAYO
  • Regeneron Pharmaceuticals, Inc. $1,568
$1,568 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

293 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record